L-Arginine signalling potential in the brain: The peripheral gets central

Recent Patents on CNS Drug Discovery

Volumn 4, Issue 2, 2009, Pages 137-142

  Lameu, Claudiana ^a,b   de Camargo, Antonio C M ^a   Faria, Marcella ^a  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ADMA; Arginase; ASL; ASS; CNS; L Arginine; L citrulline; Nitrosative stress and patents; NO; Polyamines; Proline rich peptides; ROS; Urea cycle; Vasodilation

Indexed keywords

AGMATINE; ARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; POLYAMINE; PROLINE; PROLINE RICH PEPTIDE; PROTEIN ARGININE METHYLTRANSFERASE; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER;

AMINO ACID COMPOSITION; AMINO ACID METABOLISM; ANTICONVULSANT ACTIVITY; BLOOD BRAIN BARRIER; CATABOLISM; DRUG TARGETING; ENZYME SUBSTRATE; NEUROMODULATION; PATENT; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; VASODILATATION; ANIMAL; BIOLOGICAL MODEL; BRAIN; DRUG EFFECT; ENERGY METABOLISM; HUMAN; METABOLISM; PHYSIOLOGY;

AMINO ACID TRANSPORT SYSTEMS, BASIC; ANIMALS; ARGININE; BRAIN; ENERGY METABOLISM; HUMANS; MODELS, BIOLOGICAL; NITRIC OXIDE; SIGNAL TRANSDUCTION;

EID: 68849108683     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488909788453004     Document Type: Review

References (52)

1. Wu G, Morris SM Jr. Arginine metabolism: Nitric oxide and beyond. Biochem J 1998; 336: 1-17.
2. Featherston WR, Rogers QR, Freedland RA. Relative importance of kidney and liver in synthesis of arginine by the rat. Am J Physiol 1973; 224(1): 127-129.
3. Aminlari M, Shahbazkia HR, Esfandiari A. Distribution of arginase in tissues of cat (Felis catus). J Feline Med Surg 2007; 9(2): 133-139.
4. Moinard C, Cynober L. Citrulline: A new player in the control of nitrogen homeostasis. J Nutr 2007; 137(6 Suppl 2): 1621S-1625S.
5. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev 2000; 80: 1107-1213.
6. Crim MC, Calloway DH, Margen S. Creatine metabolism in men: Urinary creatine and creatinine excretions with creatine feeding. J Nutr 1975; 105: 428-438.
7. Stead LM, Au KP, Jacobs RL, et al. Methylation demand and homocysteine metabolism: Effects of dietary provision of creatine and guanidinoacetate. Am J Physiol 2001; 281: E1095-E1100.
8. Umans JG, Levi R. Nitric oxide in the regulation of blood flow and arterial pressure. Annu Rev Physiol 1995; 57: 771-790.
9. Bolotina VM, Najibi S, Palacino JJ, et al. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994; 368(6474): 850-853.
10. Murphy ME, Brayden JE. Nitric oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive potassium channels. J Physiol 1995; 486 (Pt 1): 47-58
11. Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Annu Rev Physiol 1995; 57: 683-706.
12. Lin HC, Wan FJ, Cheng KK, Tseng CJ. Nitric oxide signaling pathway mediates the L-arginine-induced cardiovascular effects in the nucleus tractus solitarii of rats. Life Sci 1999; 65(23): 2439-2451.
13. Van Guldener C, Nanayakkara PW, Stehouwer CD. Homocysteine and asymmetric dimethylarginine (ADMA): Biochemically linked but differently related to vascular disease in chronic kidney disease. Clin Chem Lab Med 2007; 12: 1683-1687.
14. Krause CD, Yang ZH, Kim YS, et al. Protein arginine methyltransferases: Evolution and assessment of their pharmacological and therapeutic potential. Pharmacol Ther 2007; 113(1): 50-87.
15. Böger RH. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med 2003; 41(11): 1467-1472.
16. Reis DJ, Regunathan S. Agmatine: An endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. J Auton Nerv Syst 1998; 72(2-3): 80-85.
17. Reis DJ, Regunathan S. Agmatine: An endogenous ligand at imidazoline receptors is a novel neurotransmitter. Ann N Y Acad Sci 1999; 881: 65-80.
18. Hayashi Y, Hattori Y, Moriwaki A, Lu YF, Hori Y. Increases in brain polyamine concentrations in chemical kindling and single convulsion induced by pentylenetetrazol in rats. Neurosci Lett 1993; 149(1): 63-66.
19. Demehri S, Homayoun H, Honar H, et al. Agmatine exerts anticonvulsant effect in mice: Modulation by alpha 2-adrenoceptors and nitric oxide. Neuropharmacology 2003; 45(4): 534-542.
20. Tahsili-Fahadan P, Yahyavi-Firouz-Abadi N, Khoshnoodi MA, et al. Agmatine potentiates morphine-induced conditioned place preference in mice: Modulation by alpha2-adrenoceptors. Neuropsychopharmacology 2006; 31(8): 1722-1732.
21. Merimee TJ, Rabinovitz D, Riggs L, et al. Plasma growth hormone after arginine injection. N Engl J Med 1967; 276: 434-439.
22. Giugliano D, Marfella R, Verrazzo G, et al. The vascular effects of L-Arginine in humans. The role of endogenous insulin. J Clin Invest 1997; 99(3): 433-438.
23. Silva MT, Rose S, Hindmarsh JG, Jenner P, Marsden CD. L-arginine produces NO-independent increases in dopamine efflux in rat striatum. Neuroreport 1998; 9(1): 149-152.
24. Li G, Regunathan S, Barrow CJ, et al. Agmatine: An endogenous clonidine-displacing substance in the brain. Science 1994; 263(5149): 966-969.
25. Reis DJ, Li G, Regunathan S. Endogenous ligands of imidazoline receptors: Classic and immunoreactive clonidine-displacing substance and agmatine. Ann N Y Acad Sci 1995; 763: 295-313.
26. Böger RH. The pharmacodynamics of L-arginine. J Nutr 2007; 137(6 Suppl 2): 1650S-1655S.
27. Bode-Böger SM, Böger RH, Löffler M, et al. L-Arginine stimulates NO-dependent vasodilation in humans - effect of somatostatin pretreatment. J Invest Med 1999; 47: 43-50.
28. Calver A, Collier J, Leone A, et al. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens 1993; 7: 193-194.
29. Kanagy NL. Alpha(2)-adrenergic receptor signalling in hypertension. Clin Sci (Lond) 2005; 109(5): 431-437.
30. Berkowitz DE, White R, Li D, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003; 108: 2000-2006.
31. Bachetti T, Comini L, Francolini G, et al. Arginase pathway in human endothelial cells in pathophysiological conditions. J Mol Cell Cardiol 2004; 37: 515-523.
32. Xu W, Kaneko FT, Zheng S, et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 2004; 18: 1746-1748.
33. Zhang C, Hein TW, Wang W, et al. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 2004; 44: 935-943.
34. Chicoine LG, Paffett ML, Young TL, Nelin LD. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol 2004; 287: L60-68.
35. Nakaki T, Hishikawa K. The arginine paradox. Nippon Yakurigaku Zasshi 2002; 119(1): 7-14.
36. Ridnour LA, Thomas DD, Mancardi D, et al. The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations. Biol Chem 2004; 385(1): 1-10.
37. Hecker M, Sessa WC, Harris HJ, et al. The metabolism of L-arginine and its significance for the biosynthesis of endotheliumderived relaxing factor: Cultured endothelial cells recycle L-citruline to L-arginine. Proc Natl Acad Sci USA 1990; 87: 8612-8616.
38. Flam BR, Eichler DC, Solomonson LP. Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric Oxide 2007; 17(3-4): 115-121.
39. Bernstein HG, Muller M. The cellular localization of the L-ornithine decarboxylase/polyamine system in normal and diseased central nervous systems. Prog Neurobiol 1999; 57(5): 485-505.
40. Shin WW, Fong WF, Pang SF, Wong PC. Limited blood-brain barrier transport of polyamines. J Neurochem 1985; 44(4): 1056-1059.
41. Seiler N, Raul F. Polyamines and apoptosis. J Cell Mol Med 2005; 9: 623-642.
42. Drolet G. Radical scavenging properties of polyamines. Phytochemistry 1986; 25: 367-371.
43. Lovaas E, Carlin G. Spermine: An anti-oxidant and antiinflammatory agent. Free Radic Biol Med 1991; 11: 455-461.
44. Reis DJ, Regunathan S. Is agmatine a novel neurotransmitter in brain? Trends Pharmacol Sci 2000; 21: 187-193.
45. Worcel, M.: US2005010935 (2005).
46. Sarama, R.J., Niehoff, R.L.: US2001002382 (2001).
47. Camargo, A., Ianzer, D., Silva, C., Gomes, C., Guerreiro, J.: BR2007000003 (2007).
48. Guerreiro JR, Lameu C, Oliveira EF, et al. Argininosuccninate synthase (AsS) is a novel target for a snake venom antihypertensive oligopeptide. J Biol Chem 2009 (Submitted).
49. Lameu C, Guerreiro JR, Oliveira EF, et al. Induction of calcium signaling by a proline-rich oligopeptide of Bothrops jararaca. Cell Mol Life Sci 2009 (Submitted).
50. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990; 87(2): 682-685.
51. Schmidt HH, Pollock JS, Nakane M, et al. Purification of a soluble isoform of guanylyl cyclase-activating-factor synthase. Proc Natl Acad Sci USA 1991; 88(2): 365-369.
52. Smith CG, Vane JR. The discovery of captopril. FASEB J 2003; 17(8): 788-789.